

Two awards for HalioDx

- Laureate of the 2nd edition of the Worldwide Innovation Challenge
 - Seal of Excellence Certificate by the European Commission

Marseille - France, May 26, 2016 – HalioDx, a novel company that designs and develops a new class of immune oncology scoring tests for cancer diagnostics, announced that the company is laureate of the 2nd edition of the French Worldwide Innovation Challenge and it has also been awarded with a Seal of Excellence Certificate by the European Commission.

HalioDx is one of the few companies selected in the 2nd edition of the Worldwide Innovation Challenge, launched by the French government, in the “personalized medicine” topic, making the company eligible to a grant from BPI France to support the development of a *new CD8/PD-L1 assay in lung cancer as an efficient tool for the stratification of patients before and during their treatment by an anti-PD-1/PD-L1 checkpoint inhibitor*.

The goal of the Worldwide Innovation Challenge is to foster talent and bring out future champions of the French economy, by identifying and providing support for the growth of both French and foreign entrepreneurs whose innovation projects have significant implications for the French economy.

HalioDx has been also awarded with Seal of Excellence Certificate by the European Commission for *Immunoscore®*, an immune based-test to predict the risk of recurrence and response to adjuvant therapies in colon cancer patients. This innovative project was submitted under the Horizon 2020's SME instrument phase 2 call H2020-SMEInst-2014-2015 and successfully met the 3 award criteria - excellence, impact, quality and efficiency of implementation - in a highly competitive evaluation process conducted by an international panel of independent experts.

Bringing personalized medicine tools to the bed of cancer patients is the mission of HalioDx. *“Innovation in personalized medicine, especially in oncology, is a major challenge with potential benefits to all stakeholders of the healthcare systems. We are thus delighted to be recognized and supported as a promising actor in this field by both the French government and the European Commission.”* says Vincent Fert, CEO of HalioDx. *“These distinctions confirm our ambition in making our immune oncology scoring tests standard assays to improve cancer patient stratification and ultimately help clinicians in the way they manage patient treatment.”*

About HalioDx SAS

The Immune Response to Cancer Diagnostics

By precisely measuring the immune reaction in and around the tumor, HalioDx tests allow the clinician to determine the degree of severity of the patient's disease and predict the response to treatment, regardless of the cancer stage or the molecular class.

HalioDx designs and develops a unique range of immune scoring tests, whose first-in-class product is Immunoscore[®]. Considered a future diagnostic standard in Oncology, this biomarker has already demonstrated strong prognostic value in colorectal cancer. HalioDx was founded in 2014 by the former management team of Ipsogen (leader in the molecular diagnosis of leukemia), and a pioneer in integrative immunology and oncology, Dr. Jérôme Galon. HalioDx benefits of worldwide licences on a broad portfolio of IP rights on immuno-oncology biomarkers (including the Immunoscore[®] technology) developed by Dr. Jérôme Galon, Research Director at Inserm, and his team (Inserm UMRS1138) at Cordeliers Research Center, Paris, France.

HalioDx has an experienced team of 80 employees and compliant facilities to develop, manufacture, deliver and market in vitro diagnostic products and services in immuno-oncology.

For more information, please visit: www.halioldx.com

HalioDx and Immunoscore are registered trademarks.

Contacts

HalioDx

ATCG Press

Marie Puvieux (France), Mob: +33 (0)6 10 54 36 72

 twitter.com/halioldx  <https://www.linkedin.com/company/halioldx>